NY-ESO-1

from Wikipedia, the free encyclopedia

NY-ESO-1 ( English New York esophageal squamous cell carcinoma-1 , also Cancer / testis antigen 1 , Cancer / testis antigen 6.1 , L antigen family member 2 ) is a human tumor antigen from the group of tumor testis antigens .

properties

NY-ESO-1 has a length of 180 amino acids in isoform 1 and a mass of 17,992 Da as well as 168 amino acids and 16,192 Da in isoform 2. It does not occur as a tumor antigen in healthy cells (except in immunoprivileged spermatocytes ), but does often in different tumors expressing such. B. breast , prostate , ovarian , lung , neuroblastoma , metastatic melanoma , myeloma and synovial sarcoma . It is therefore a target antigen in the development of cancer vaccines and cancer immunotherapies with adoptive cell transfer .

Individual evidence

  1. ↑ C. Criscitiello, G. Curigliano: Immunotherapy of Breast Cancer. In: Progress in tumor research. Volume 42, 2015, pp. 30-43, doi : 10.1159 / 000437183 , PMID 26377084 .
  2. ↑ G. Sonpavde, M. Wang, LE Peterson, HY Wang, T. Joe, MP Mims, D. Kadmon, MM Ittmann, TM Wheeler, AP Gee, RF Wang, TG Hayes: HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer. In: Investigational new drugs. Volume 32, number 2, April 2014, pp. 235-242, doi : 10.1007 / s10637-013-9960-9 , PMID 23609828 , PMC 4100683 (free full text).
  3. ↑ CL Schwab, DP English, DM Roque, M. Pasternak, AD Santin: Past, present and future targets for immunotherapy in ovarian cancer. In: Immunotherapy. Volume 6, number 12, 2014, pp. 1279–1293, doi : 10.2217 / imt.14.90 , PMID 25524384 , PMC 4312614 (free full text).
  4. ^ A b D. K. Krishnadas, F. Bai, KG Lucas: Cancer testis antigen and immunotherapy. In: ImmunoTargets and therapy. Volume 2, 2013, pp. 11-19, doi : 10.2147 / ITT.S35570 , PMID 27471684 , PMC 4928360 (free full text).
  5. ^ GQ Phan, SA Rosenberg: Adoptive cell transfer for patients with metastatic melanoma: the potential and promise of cancer immunotherapy. In: Cancer Control . Volume 20, Number 4, October 2013, pp. 289-297, PMID 24077405 .
  6. ^ A b J.F. San Miguel, B. Paiva, JJ Lasarte: Engineering Anti-myeloma Responses Using Affinity-Enhanced TCR-Engineered T Cells. In: Cancer cell. Volume 28, number 3, September 2015, pp. 281-283, doi : 10.1016 / j.ccell.2015.08.009 , PMID 26373276 .
  7. ↑ M. Burgess, H. Tawbi: Immunotherapeutic approaches to sarcoma. In: Current treatment options in oncology. Volume 16, number 6, June 2015, p. 26, doi : 10.1007 / s11864-015-0345-5 , PMID 25975445 .
  8. ^ A. Esfandiary, S. Ghafouri-Fard: New York esophageal squamous cell carcinoma-1 and cancer immunotherapy. In: Immunotherapy. Volume 7, number 4, 2015, pp. 411-439, doi : 10.2217 / imt.15.3 , PMID 25917631 .
  9. ↑ M. Tagliamonte, A. Petrizzo, ML Tornesello, FM Buonaguro, L. Buonaguro: Antigen-specific vaccines for cancer treatment. In: Human vaccines & immunotherapeutics. Volume 10, number 11, 2014, pp. 3332–3346, doi : 10.4161 / 21645515.2014.973317 , PMID 25483639 , PMC 4514024 (free full text).